Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$15.71
-4.8%
$15.06
$6.69
$16.89
$832.14M1.88760,779 shs541,043 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$4.37
+2.3%
$4.77
$1.76
$12.46
$198.93M-0.16369,667 shs183,136 shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$6.44
-8.0%
$8.54
$6.42
$18.63
$695.12M0.952.01 million shs2.93 million shs
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$12.03
-5.8%
$12.34
$7.16
$15.03
$754.90M0.851.34 million shs1.14 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%+2.10%+9.99%+55.90%+129.62%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
0.00%-9.53%-4.47%-38.03%+110.86%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
0.00%-11.84%-27.46%-14.43%-60.94%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
0.00%-4.34%-1.01%+18.46%+5.80%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$15.71
-4.8%
$15.06
$6.69
$16.89
$832.14M1.88760,779 shs541,043 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$4.37
+2.3%
$4.77
$1.76
$12.46
$198.93M-0.16369,667 shs183,136 shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$6.44
-8.0%
$8.54
$6.42
$18.63
$695.12M0.952.01 million shs2.93 million shs
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$12.03
-5.8%
$12.34
$7.16
$15.03
$754.90M0.851.34 million shs1.14 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%+2.10%+9.99%+55.90%+129.62%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
0.00%-9.53%-4.47%-38.03%+110.86%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
0.00%-11.84%-27.46%-14.43%-60.94%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
0.00%-4.34%-1.01%+18.46%+5.80%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CryoPort, Inc. stock logo
CYRX
CryoPort
2.80
Moderate Buy$15.11-3.81% Downside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$10.50140.27% Upside
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
2.50
Moderate Buy$28.20337.89% Upside
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2.82
Moderate Buy$29.29143.44% Upside

Current Analyst Ratings Breakdown

Latest NERV, CYRX, ZVRA, and SPRY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
Lower Price TargetOutperform$25.00 ➝ $24.00
6/24/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Reiterated RatingSell (D-)
6/24/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Reiterated RatingBuy
6/23/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Reiterated RatingBuy$26.00
6/10/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Boost Price TargetBuy$25.00 ➝ $29.00
6/10/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Boost Price TargetBuy$25.00 ➝ $35.00
6/9/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Boost Price TargetBuy$24.00 ➝ $29.00
6/9/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Reiterated RatingBuy
6/9/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Reiterated RatingOutperform
6/9/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Reiterated RatingBuy$23.00 ➝ $27.00
6/9/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Boost Price TargetMarket Outperform$18.00 ➝ $25.00
(Data available from 7/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CryoPort, Inc. stock logo
CYRX
CryoPort
$176.18M4.49N/AN/A$9.19 per share1.71
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/A($3.25) per shareN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$84.28M7.59N/AN/A$1.16 per share5.55
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$106.47M6.68$0.89 per share13.50$2.75 per share4.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M$1.3511.64N/AN/A41.57%-7.92%-4.79%8/4/2026 (Estimated)
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$293.42M-$29.16N/A0.91N/AN/AN/A-32.63%8/13/2026 (Estimated)
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$171.30M-$2.01N/AN/AN/A-200.00%-153.61%-60.85%8/12/2026 (Estimated)
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$83.23M$1.996.0512.66N/A101.58%51.49%28.86%8/11/2026 (Estimated)

Latest NERV, CYRX, ZVRA, and SPRY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.1933N/AN/AN/AN/AN/A
8/12/2026Q2 2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.4766N/AN/AN/A$31.33 millionN/A
8/11/2026Q2 2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$0.08N/AN/AN/A$33.88 millionN/A
8/4/2026Q2 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20N/AN/AN/A$48.21 millionN/A
5/15/2026Q1 2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.53-$0.61-$0.08-$0.61$22.20 million$22.68 million
5/6/2026Q1 2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$0.06$0.18+$0.12$0.60$31.96 million$36.22 million
5/5/2026Q1 2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.13-$0.17-$0.04-$2.86N/AN/A
5/4/2026Q1 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.23-$0.03-$0.25$44.86 million$47.80 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.09
2.00
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
17.65
17.65
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
2.79
4.94
4.77
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
N/A
4.89
4.84

Institutional Ownership

CompanyInstitutional Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
68.16%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
35.03%

Insider Ownership

CompanyInsider Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
9.50%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
1.70%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
33.80%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.40 million45.61 millionOptionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
946.59 million45.80 millionNot Optionable
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
9099.30 million65.74 millionOptionable
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2059.12 million57.70 millionOptionable

Recent News About These Companies

Zevra Therapeutics: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

CryoPort stock logo

CryoPort NASDAQ:CYRX

$15.71 -0.80 (-4.85%)
Closing price 04:00 PM Eastern
Extended Trading
$15.65 -0.06 (-0.39%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$4.37 +0.10 (+2.34%)
Closing price 04:00 PM Eastern
Extended Trading
$4.37 0.00 (0.00%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

ARS Pharmaceuticals stock logo

ARS Pharmaceuticals NASDAQ:SPRY

$6.44 -0.56 (-8.00%)
Closing price 04:00 PM Eastern
Extended Trading
$6.54 +0.11 (+1.63%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Zevra Therapeutics stock logo

Zevra Therapeutics NASDAQ:ZVRA

$12.03 -0.74 (-5.79%)
Closing price 04:00 PM Eastern
Extended Trading
$12.33 +0.30 (+2.49%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.